These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31586354)

  • 1. Gene Therapy for Huntington's Disease Using Targeted Endonucleases.
    Dabrowska M; Olejniczak M
    Methods Mol Biol; 2020; 2056():269-284. PubMed ID: 31586354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
    Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
    Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
    Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.
    Dabrowska M; Juzwa W; Krzyzosiak WJ; Olejniczak M
    Front Neurosci; 2018; 12():75. PubMed ID: 29535594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing an Expanded Trinucleotide Repeat Tract into the Human Genome for Huntington's Disease Modeling In Vitro.
    Malankhanova T; Sorokin M; Medvedev S; Zakian S; Malakhova A
    Curr Protoc Hum Genet; 2020 Jun; 106(1):e100. PubMed ID: 32469433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
    Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver B; Lee JM
    Elife; 2024 Jun; 12():. PubMed ID: 38869243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington's disease knock-in mice is blocked by Mlh1 knock-out.
    Loupe JM; Pinto RM; Kim KH; Gillis T; Mysore JS; Andrew MA; Kovalenko M; Murtha R; Seong I; Gusella JF; Kwak S; Howland D; Lee R; Lee JM; Wheeler VC; MacDonald ME
    Hum Mol Genet; 2020 Nov; 29(18):3044-3053. PubMed ID: 32876667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introducing an expanded CAG tract into the huntingtin gene causes a wide spectrum of ultrastructural defects in cultured human cells.
    Morozova KN; Suldina LA; Malankhanova TB; Grigor'eva EV; Zakian SM; Kiseleva E; Malakhova AA
    PLoS One; 2018; 13(10):e0204735. PubMed ID: 30332437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
    Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal instability during neurogenesis in Huntington's disease.
    Ruzo A; Croft GF; Metzger JJ; Galgoczi S; Gerber LJ; Pellegrini C; Wang H; Fenner M; Tse S; Marks A; Nchako C; Brivanlou AH
    Development; 2018 Jan; 145(2):. PubMed ID: 29378824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
    Conforti P; Camnasio S; Mutti C; Valenza M; Thompson M; Fossale E; Zeitlin S; MacDonald ME; Zuccato C; Cattaneo E
    Neurobiol Dis; 2013 Feb; 50():160-70. PubMed ID: 23089356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.